Nuke Regulators Debate Releasing Radioactive Patients Home
Published Date: 8/3/2026
Notice
Summary
The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on August 17, 2026, to discuss and provide recommendations from the subcommittee on Regulatory Guide 8.39, "Release of Patients Administered Radioactive Material" review of proposed patient release revisions in the Reforming and Modernizing the NRC's Radiation Protection Framework proposed rulemaking and draft revisions to Regulatory Guide 8.39. Meeting information, including a copy of the agenda and handouts, will be available on the ACMUI's Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/doc- collections/acmui/meetings/2026 or by emailing Ms. Sarah Hoenig at the contact information below.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13687, Implementation of the National Environmental Policy Act
The Nuclear Regulatory Commission is updating how it follows the National Environmental Policy Act to make reviews faster, clearer, and less of a hassle. These changes affect anyone applying for nuclear licenses or permits, cutting down on paperwork and focusing only on important environmental impacts. You’ve got until August 21, 2026, to share your thoughts before the new rules take shape!
2026-12067, Fee Schedules; Fee Recovery for Fiscal Year 2026
The Nuclear Regulatory Commission is updating its fees for licenses, inspections, and special projects starting August 17, 2026. These changes make sure the NRC covers nearly all its costs while setting clear fee limits to keep prices predictable and fair. If you hold a license or apply for one, expect some fee adjustments that help the NRC run smoothly and efficiently.
2026-08015, Generic Environmental Impact Statement for Licensing of New Nuclear Reactors
The Nuclear Regulatory Commission just updated the rules for checking the environmental impact of new nuclear reactors. This makes it easier and faster to review many reactors by using a common set of environmental factors, while still looking closely at unique site details. The new rules kick in on May 26, 2026, helping companies save time and money when applying to build new reactors.
2026-06048, Risk-Informed, Technology-Inclusive Regulatory Framework for Advanced Reactors
The Nuclear Regulatory Commission is updating its rules to make it easier and faster to approve new types of nuclear reactors, not just the old light-water ones. This change helps companies building advanced reactors by using smarter, risk-based rules that fit new technology. The new rules start on April 29, 2026, and could save time and money for the nuclear industry and the public.
2026-04823, Fee Schedules; Fee Recovery for Fiscal Year 2026
The Nuclear Regulatory Commission (NRC) is updating its fees for licenses, inspections, and special projects for fiscal year 2026. These changes aim to cover nearly all NRC costs and set fixed fee limits to boost efficiency and fairness. If you’re involved with the NRC, get ready for new fees by September 30, 2026, and don’t miss the April 13 deadline to share your thoughts!
2025-14147, Fee Schedules; Fee Recovery for Fiscal Year 2025
The U.S. Nuclear Regulatory Commission fixed a typo in their fee schedule for 2025. This update affects companies and government agencies that pay licensing and inspection fees, making sure the right amounts are charged. The corrected fees kick in soon, so everyone can plan their budgets without surprises!
Previous / Next Documents
Previous: 2026-15630, Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts." This draft guidance is intended to help applicants develop container closure systems and device constituent parts for proposed biosimilar and interchangeable biosimilar products. This draft guidance expands on and clarifies the Agency's recommendations and expectations regarding the development of delivery devices and container closure systems described in Q.I.4 of the guidance for industry entitled "Questions and Answers on Biosimilar Development and the BPCI Act" and the guidance for industry entitled "Considerations in Demonstrating Interchangeability With a Reference Product" for biosimilar and interchangeable biosimilar products, respectively.
Next: 2026-15633, Notice Regarding 340B Rebate Model Pilot Program
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------